My International Normalized Ratio (INR) is 1.8 while on warfarin; how should the warfarin dose be adjusted to reach the therapeutic range?

Management of INR 1.8 on Warfarin

For a single INR of 1.8 in a patient with previously stable therapeutic INRs (target 2.0-3.0), continue the current warfarin dose without adjustment and recheck the INR within 1-2 weeks 1.

Rationale for No Dose Adjustment

An INR of 1.8 falls within the range where evidence supports watchful waiting rather than dose modification. The 2012 American College of Chest Physicians (ACCP) guidelines specifically recommend continuing the current dose for single out-of-range INRs that are 0.5 below or above the therapeutic range 1. Since your INR of 1.8 is only 0.2 below the lower therapeutic limit of 2.0, this clearly falls within the guideline parameters.

Key supporting evidence:

• A randomized controlled trial comparing one-time dose adjustments versus no change for INRs between 1.5-4.4 found no significant difference in therapeutic range achievement at 2-week follow-up (44% vs 40%, p=0.75) 1
• An observational study of 3,961 patients demonstrated that warfarin doses did not need adjustment for INRs between 1.7-3.3 1
• A 2022 study of 45,351 slightly out-of-range INRs found only a minimal difference between watchful waiting and dose changes (58.9% vs 60.0% achieving therapeutic range), which was statistically significant but clinically unimportant 2

When Dose Adjustment IS Warranted

You should consider adjusting the warfarin dose if:

• Multiple consecutive subtherapeutic INRs occur (not just a single value)
• The INR is <1.5 (more than 0.5 below therapeutic range)
• There is an identifiable cause for the low INR (new medication, dietary changes, missed doses) that has been corrected
• The patient has high thrombotic risk (mechanical heart valve, recent VTE, recurrent thromboembolism)

Bridging Therapy Not Recommended

Do not routinely bridge with heparin or low molecular weight heparin for a single subtherapeutic INR 1. Studies show no significant difference in thromboembolic events between patients with single low INRs and those with therapeutic INRs, even in high-risk populations including mechanical heart valve patients 1.

Follow-Up Strategy

• Recheck INR in 1-2 weeks 1
• Investigate potential causes: medication changes, dietary vitamin K intake changes, missed doses, illness
• If the repeat INR remains subtherapeutic or continues to trend downward, then adjust the weekly warfarin dose by 5-20% 3
• Ensure patient adherence and consistent vitamin K intake

Common Pitfalls to Avoid

1. Over-correction: Making dose changes for every minor INR fluctuation leads to "chasing the INR" and actually worsens anticoagulation control
2. Premature bridging: Unnecessary heparin bridging increases bleeding risk without proven benefit for single low INRs
3. Large dose adjustments: If adjustment becomes necessary, modify the total weekly dose by only 5-20%, not individual daily doses 3
4. Inadequate follow-up: Failing to recheck the INR within 1-2 weeks may miss a progressive decline requiring intervention

Context Matters

This recommendation assumes:

• Previously stable anticoagulation (not a new warfarin start)
• Target INR range of 2.0-3.0 (standard for most indications including atrial fibrillation and VTE) 4
• No active bleeding or urgent procedures planned
• No new interacting medications or significant dietary changes

The FDA labeling confirms that the therapeutic target for most indications is INR 2.0-3.0, with dose adjustments based on PT/INR response 4.